BridgeMD
New treatment option for Esophageal Squamous Cell Carcinoma
Official title Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
ClinicalTrials.gov ID: NCT06576973
What this study is testing
What is Adbelimumab, Albumin paclitaxel, Carboplatin, Apatinib?
Adbelimumab, Albumin paclitaxel, Carboplatin, Apatinib is an investigational medicine, being studied as a potential treatment for esophageal squamous cell carcinoma.
Also referred to as Esophagectomy.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Esophageal cancer is a prevalent digestive tract tumor, with around 400,000 new cases and 300,000 deaths globally each year. In the past few decades, surgery, radiotherapy, chemotherapy and other treatments were continuously improved, however, the mortality of esophageal squamous cell carcinoma (ESCC) patients was not significantly decreased.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Signed informed consent.
- Patients age 18 to 75 years old.
- Primary resectable, histologically confirmed esophageal squamous cell cancer.
- Esophageal squamous cell carcinoma the clinical stage was II-IVA (according to AJCC TNM stage, 8th edition).
- ECOG PS 0-1.
You likely can't join if
- With significant cardiovascular disease.
- Current treatment with anti-viral therapy or HBV.
- Female patients who are pregnant or lactating.
- History of malignancy within 5 years prior to screening.
- Active or history of autoimmune disease or immune deficiency.
- Signs of distant metastases.
See the full eligibility criteria
- Signed informed consent.
- Patients age 18 to 75 years old.
- Primary resectable, histologically confirmed esophageal squamous cell cancer.
- Esophageal squamous cell carcinoma the clinical stage was II-IVA (according to AJCC TNM stage, 8th edition).
- ECOG PS 0-1.
- No distant metastasis, the diseases could be resectable assessed by thoracic oncologist.
- With significant cardiovascular disease.
- Current treatment with anti-viral therapy or HBV.
- Female patients who are pregnant or lactating.
- History of malignancy within 5 years prior to screening.
- Active or history of autoimmune disease or immune deficiency.
- Signs of distant metastases.
The study team makes the final eligibility decision.
Where it's taking place
- Hangzhou, China, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hangzhou, China, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.